{"id":"W4417001866","doi":"10.1182/blood-2025-763","title":"Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Tolerability; Refractory (planetary science); Regimen; Phases of clinical research; Acute leukemia; Leukemia; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001825226,0.0007824397,0.0014471,0.0002782606,0.0003003771,0.0008893607,0.0007439184,0.0008774331,0.007096415],"category_scores_gemma":[0.0009281496,0.0003116918,0.0008689902,0.0004432656,0.0002291724,0.000605273,0.0003077263,0.002125655,0.001378884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009389655,"about_ca_system_score_gemma":0.001165163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009183209,"about_ca_topic_score_gemma":0.004277276,"domain_scores_codex":[0.9995652,0.0002008058,0.0000400789,0.00004939841,0.00008042905,0.0000640886],"domain_scores_gemma":[0.999443,0.000100968,0.0001541629,0.00004000038,0.0000879004,0.0001738771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2869571,0.01864994,0.01621117,0.003817298,0.002684225,0.0006544848,0.0004180039,0.004103737,0.1024386,0.001021969,0.07455676,0.4884867],"study_design_scores_gemma":[0.4621188,0.2934076,0.06668577,0.000575017,0.002990786,0.002011117,0.000137549,0.003518411,0.02453615,0.001194173,0.1427147,0.000110059],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8853962,0.03280092,0.003959593,0.005747501,0.0005391438,0.01072592,0.03658859,0.0008895139,0.02335258],"genre_scores_gemma":[0.8767659,0.01898795,0.01266883,0.008458054,0.0006185114,0.008728151,0.0574738,0.0002196479,0.01607902],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007096415,"threshold_uncertainty_score":0.02373987,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01024731356587494,"score_gpt":0.2959461322324716,"score_spread":0.2856988186665967,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}